By Sheeba M. | April 17, 2026
Trulieve’s Florida Dominance Faces Test as Adult-Use Rollout Accelerates
Trulieve Cannabis (TCNNF) has built the most dominant single-state position in the cannabis industry. The company operates 203 dispensaries in Florida — more than the next three operators combined — and generated $924 million in revenue for fiscal year 2025, nearly all of it from the state’s medical-only market. That market is about to change in a significant way.
Florida’s adult-use cannabis law took effect in early 2026, and the initial impact on Trulieve’s business has been more expansion of the total addressable market than cannibalization of existing medical patients. Early recreational sales figures from the first eight weeks suggest average ticket sizes are running slightly below the medical average — a common dynamic as price-sensitive recreational consumers enter — but total transactions have increased by roughly 35%, which more than offsets the per-transaction margin compression.
Why Florida Is the Most Important State Market Right Now
Florida is the third-largest state by population in the country. A fully ramped adult-use cannabis market in Florida is a multi-billion dollar opportunity, and Trulieve has the infrastructure in place to capture a disproportionate share. But the company has competitors who are not going to sit idle. Multi-state operators like Green Thumb (GTBIF), Ayr Wellness, and Cresco Labs (CRLBF) have all been building Florida retail presence over the past two years, and they’re entering the adult-use era with significant advertising budgets and brand investments that Trulieve — dominant in medical but less differentiated in rec — will need to match.
The Numbers Underneath
Trulieve’s Q4 2025 revenue was $231 million, up 4% sequentially, with adjusted EBITDA of $72 million — a 31% margin that is the envy of the MSO sector. The company generated $48 million in free cash flow for the full year, which it has been using to pay down debt and fund its Florida expansion. Net debt as of Q4 2025 stood at $312 million, down from $410 million at the start of the year.
The 2026 analyst consensus is for revenue of $1.05 billion — about a 13% increase — driven by the adult-use ramp in Florida. At the current stock price of roughly $12.50, TCNNF trades at about 8x 2026 EV/EBITDA, a discount to its five-year average of 10.5x. That discount exists because investors are uncertain about the competitive response from other MSOs in Florida — and that uncertainty is the的核心 risk.
What Insiders Are Doing
Trulieve’s CFO purchased 15,000 shares in the open market in February 2026 at around $11.80 — not a large position but a vote of confidence at a price that’s now slightly underwater. Larger insider moves have come from board members exercising and selling legacy options, which doesn’t signal conviction either way. The founder and CEO remain significant holders, which provides some floor.
The broader MSO sector has seen institutional ownership tick up in Q1 2026, per 13F filings available so far — a sign that value-oriented cannabis investors are starting to find the valuations attractive after two years of sector-wide multiple compression. Trulieve, as the largest pure-play Florida story, stands to benefit from that rotation.
Sources
- Trulieve Investor Relations — FY2025 earnings and operational metrics
- Florida Office of Medical Marijuana Use — Dispensary count and patient registration data
- SEC EDGAR — TCNNF Filings — Annual reports and insider transaction disclosures
Track cannabis stocks with the Weedstock Real-Time Tracker